Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lybalvi vs Olanzapine for Weight Gain in Schizophrenia
NCT02694328Phase 3Completed
- Sponsor
- Alkermes
- Start
- Mar 2016
- Primary completion
- Nov 2018
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of olanzapine + samidorphan in schizophrenia (2 arms), sponsored by Alkermes. Primary endpoints: Percent Change From Baseline in Body Weight at Week 24 and Percentage of Participants With >/= 10% Weight Gain at Week 24. Started Mar 2016; status: completed.
02
Drugs
olanzapine + samidorphan
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02694328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02694328.